Open for inclusion

A phase I multicenter open-label study of BGB324 as a single agent and in combination with cytarabine in patients with acute myeloid leukemia or high/intermediate (int-2) risk myelodysplastic syndrome wich overexpresses axl

Cancer type: Leukemia

Phase: I

Principal Investigator: Gjertsen Bjørn Tore

Country: NO

Keywords: Norway, Bergen

Status: Open for inclusion

Link to